In silico evaluation of bioavailability, pharmacokinetics and toxicological properties of selected dual inhibitors of acetylcholinesterase and monoamino oxidase-B for the treatment of Alzheimer's disease
Computational findings support in vitro and in vivo evaluation of compounds 1, 3, 6, 13, 14, 30, 31, 34, 36-38, and 44-46 as dual AChE/MAO B inhibitors and potential new drug candidates for AD treatment.